Jejunostomy in the palliative treatment of gastric cancer: A clinical prognostic score

Table 3 Characteristics of jejunostomy patients according to the risk group-score validation cohort (n = 40)

Variables	J2-score validation cohort		P value
	Low-risk	High-risk
	n = 21 (%)	n = 19 (%)
Sex			0.721
Female	6 (28.6)	4 (21.1)
Male	15 (71.4)	15 (78.9)	0.072
Age (years)
mean (SD)	59.7 (12.4)	66.7 (11.4)
BMI (kg/m2)			0.074
mean (SD)	21.4 (3.5)	19.0 (4.7)
CCI			0.001
0	21 (100)	11 (57.9)
≥ 1	0 (0)	8 (42.1)
ASA class			0.002
I/II	16 (76.2)	5 (26.3)
III/IV	5 (23.8)	14 (73.7)
Hemoglobin (g/dL)			0.345
mean (SD)	11.4 (2.3)	10.6 (2.4)
Albumin (g/dL)			0.047
mean (SD)	3.6 (0.6)	3.1 (0.6)
NLR			0.012
mean (SD)	3.65 (3.45)	8.81 (7.64)
Tumor size (cm)			0.731
mean (SD)	6.6 (2.6)	6.9 (3.4)
Presence of ascites on CT			0.004
Absent	14 (66.7)	4 (21.1)
Present	7 (33.3)	15 (78.9)
Lauren type			0.753
Intestinal	5 (23.8)	7 (36.8)
Diffuse/mixed	13 (61.9)	9 (47.4)
Undetermined	3 (14.3)	3 (15.8)
Number of disease sites			0.385
One (only locoregional)	7 (33.3)	4 (21.1)
Two or more	14 (66.7)	15 (78.9)
POC			1
No POC/Clavien 1-2	19 (90.5)	17 (89.5)
Clavien 3-5	2 (9.5)	2 (10.5)
Length of hospital stay (days)			0.455
Median (IQR)	3 (3-7.5)	4 (4-8)
Palliative treatment-1st Line			0.012
No	5 (23.8)	12 (63.2)
Yes	16 (76.2)	7 (36.8)
30-d mortality			0.049
No	18 (85.7)	11 (57.9)
Yes	3 (14.3)	8 (42.1)
90-d mortality			0.027
No	14 (66.7)	6 (31.6)
Yes	7 (33.3)	13 (68.4)

SD: Standard deviation; IQR: Interquartile range; POC: Postoperative complication; CCI: Charlson's comorbidity index; CT: Computed tomography; NLR: Neutrophil lymphocyte ratio; ASA: American Society of Anesthesiologists; BMI: Body mass index.